TOKYO – With a liberalized regulatory environment, Japan is rapidly emerging as a major player in regenerative medicine and is attracting more companies eager to explore the market.
TOKYO – Closer collaboration, especially information sharing, between different authorities, universities, clinical institutes as well as companies is called for to speed up biopharmaceutical development in Japan.
TOKYO — Closer collaboration, especially information sharing, between different authorities, universities, clinical institutes as well as companies is called for to speed up biopharmaceutical development in Japan.
HONG KONG – In a move that has once again highlighted concerns over the quality of some made-in-China drugs and raw materials, French regulators have raised questions regarding heparin made by a mainland company.
HONG KONG – In a move that has once again highlighted concerns over the quality of some made-in-China drugs and raw materials, French regulators have raised questions regarding heparin made by a mainland company.
HONG KONG – China’s Wuxi Biologics Co. Ltd. managed a breakthrough by getting a biological product it manufactures approved in the use of clinical trials in Belgium, making it the first-ever China-made biologic dosed in a clinical trial in the European Union (EU).
HONG KONG – China's Wuxi Biologics Co. Ltd. managed a breakthrough by getting a biological product it manufactures approved in the use of clinical trials in Belgium, making it the first-ever China-made biologic dosed in a clinical trial in the European Union (EU).
HONG KONG – After an 11-month suspension in trading, shares of Hong Kong-listed Sihuan Pharmaceutical Holdings Group Ltd. (HK:0460) plunged more than 54 percent on Monday.
